Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Levitra Market Share Hurt By Lack of Branded Ads At Launch, GSK Says

This article was originally published in The Pink Sheet Daily

Executive Summary

GSK and Bayer were hesitant to launch Levitra with full product ads because of risk info, but the Cialis branded campaign revealed consumers were not dissuaded by product risks, GSK says. Sampling and internet sales of counterfeits have slowed growth in the category.

You may also be interested in...



Lilly/Icos' Cialis Is Only Drug To Play In The Super Bowl Commercial Game

Sixty-second "product and use" spot for the erectile dysfunction agent says that "all over the world, more and more men are discovering Cialis." Tadalafil was the only drug advertised during the championship game, unlike the 2004 Super Bowl, when a Cialis commercial went up against reminder ads for Levitra.

Lilly/Icos' Cialis Is Only Drug To Play In The Super Bowl Commercial Game

Sixty-second "product and use" spot for the erectile dysfunction agent says that "all over the world, more and more men are discovering Cialis." Tadalafil was the only drug advertised during the championship game, unlike the 2004 Super Bowl, when a Cialis commercial went up against reminder ads for Levitra.

Schering-Plough Will Eye Primary Care Acquisitions To Complement Vytorin, Zetia

CEO Hassan vows not to repeat mistakes of Schering's past by relying on the cholesterol agents to carry the business for the long-term. Bayer's oral Factor Xa inhibitor is a potential acquisition candidate, depending on how the antithrombotic fares in Phase III.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS060567

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel